Following a heart attack a quarter of patients will develop heart failure and die.
Despite state-of-the-art therapy.
Cardior’s goal is to fill this treatment gap.
Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world. Our lead development program is an oligonucleotide based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury - CDR-132X.
We are in the process of building an expert drug development team around the scientific founders - Prof. Thomas Thum and Dr. Sandor Batkai.
Thomas is a researching cardiologist and one of the initial pioneers in cardiovascular noncoding RNA research. He is head of the Institute of Molecular and Translational Therapeutic Strategies and professor at the Hannover Medical School and visiting professor at the National Heart and Lung Institute of the Imperial College London. The current major research focus at his institute is to develop novel diagnostic and therapeutic noncoding RNA-based concepts in cardiovascular medicine and beyond. Thomas has an outstanding academic track record with a focus on heart failure and transcriptional biology, with over 200 publications and attracts around 1.2M Euro in grants annually. His work is regularly featured in Nature and Nature Group publications. He has filed over 20 patents, including the patents that form the basis of Cardior.
Thomas has received many national and international awards such as the Outstanding Achievement Award of the European Society of Cardiology in 2011. He also became a Fellow of both the European society of Cardiology (FESC) as well as the American Society of Cardiology (FAHA).
In 2015 Thomas was appointed organizer of the 2017 CVD Keystone meeting, International Associate Editor of the European Heat Journal (EHJ) and Scientific Advisor to the Institut Pasteur de Lille.
Thomas received the Outstanding Investigator Award from the International Society of Heart Research (ISHR) on July 1, 2015.
Claudia, currently supporting Cardior as a business advisor, is helping to manage the spin-off phase including fundraising and partnering. She brings 20 years of expertise in the health care industry and senior-level experience in consulting, in business development, marketing, PR, regulatory affairs, and technology transfer. She successfully managed a spin-off company of the University of Heidelberg, developing cardiovascular therapeutics into a major success achieving a multi-billion US-dollar deal with Bristol-Myers Squibb. She can also draw on the experience of Andreas Kranzusch, a partner at ulbrich&partner, who will oversee the financials. He is an expert in finance and administration with more than 10 years of managerial experience in life science start-ups.
Sandor is a researching cardiologist and currently holds the position of group leader of Cardiovascular Phenotyping and Translational Strategies at the Hannover Medical School. He previously headed the Cardiovascular Phenotyping Core facility at the US National Institutes of Health (NIH), where his work also required direct interaction with regulatory authorities.
Sandor is an established scientist in cardiovascular research and pharmacology with over 100 publications in high ranking scientific journals.
He is an expert in phenotyping methods, biomarker development and clinical pharmacology and experienced in industry sponsored drug development collaborations that he previously was part of with Sanofi, Jenrin Discovery Inc. and GW Pharma Inc. Sandor is the lead scientists on all proof-of-concept in-vitro and and animal studies.